The Phase 3 study (NCT05803421) investigating orforglipron (LY3502970) in participants with Type 2 Diabetes and Obesity or Overweight completed its primary study on March 16, 2026. This trial compared daily oral orforglipron with insulin glargine.
Background
Orforglipron is being investigated for the treatment of Type 2 Diabetes and Obesity or Overweight, particularly in individuals who also have an increased cardiovascular risk. The study aimed to evaluate the safety and efficacy of this daily oral medication.
Trial design
The study, identified as NCT05803421, is a Phase 3 trial with an enrollment of 2749 participants. It focused on individuals diagnosed with Type 2 Diabetes and either Obesity or Overweight, who also had an increased risk of Cardiovascular Diseases. The trial compared daily oral orforglipron (LY3502970) against insulin glargine. The main purpose was to determine the safety and efficacy of orforglipron in this population.
What this means
The primary completion of this large Phase 3 study for orforglipron marks a significant milestone in its development. With 2749 participants, the trial has gathered extensive data on the comparative safety and efficacy of orforglipron versus insulin glargine in a population with Type 2 Diabetes and Obesity or Overweight at increased cardiovascular risk. This completion indicates that the main data collection period for the primary endpoints has concluded, moving the drug closer to potential data readouts and further regulatory evaluation.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The status for study NCT05803421, titled "A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk," was updated on 2026-03-16 on clinicaltrials.gov.